HYTERA
5.7.2022 15:31:03 CEST | Business Wire | Press release
Hytera, a leading global provider of professional communications technologies and solutions, together with its subsidiaries Sepura and Teltronic, won awards in 5 categories at the International Critical Communications Awards (ICCAs) 2022 held in Vienna, Austria. The ICCAs, presented by The Critical Communications Association (TCCA), are the most prestigious awards in critical communications celebrating the very best of the sector across a variety of verticals and recognizing those who have made significant and individual contributions to the critical communications industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220705005515/en/
Hytera was firstly awarded “Best Use of Critical Communications in Transport ” for a Sri Lanka Railway (SLR) Telecommunications Project. This project enabled Hytera’s 3GPP-compliant MCS Solution to interconnect the SLR sites and provide railway personnel with real-time access to critical data. This allowed them to better serve passengers and provide a smooth and safe operation for train drivers by improving punctuality and reducing railway accidents.
Sepura also claimed an ICCA award for “Best Use of Critical Communications in Mining, Oil & Gas ” for the AutoMate App SPACE Application and SCG22 Mobile Radio which was part of the National Wireless Mining Solution. The solution contributed to the operational performance and safety of staff by enabling radio automation through geo-fencing and situational triggers in iron ore mines in Australia.
The SCU3, Sepura’s latest broadband vehicle device, won “Best MX-C Device of the Year ”. This technology aroused considerable interests amongst professional communication users looking for future-proof, powerful data capability to enhance their communications solutions.
Sepura’s Senior Specialist Diana Ball was recognized for her “Outstanding Contribution to Critical Communications ” for the development of TETRA standards that are still trusted by users to ensure interoperability between suppliers.
Teltronic’s EDESUR project was next awarded “Best Use of Critical Communications in Utilities” . The NEBULA TETRA infrastructure allowed a private electricity distribution company in Argentina to realize the real-time monitoring and fault detection of a power distribution network, and further improve company management and operational efficiency thanks to Teltronic’s unique SDM (Synchronous Data Management) technology.
In addition to securing these awards, Hytera Group was also shortlisted for a number of additional categories including:
Best MC-X Device of the Year
Hytera PDM680 Rugged MCS Radio
Teltronic RTP-800, the First MCX Cab Radio for Transport
Best MC-X solutions of the year
Sepura SCU3 Broadband Vehicle Device
Best TETRA Device of the Year
Hytera PTC680 Multi-mode Radio
Sepura SCG22 Mobile TETRA Radio
Best Use of Advanced Technology
Hytera AI-based Noise Cancellation for Two-way Radios
Best Use of Critical Communications in Public Safety
Teltronic: RESCAN, Reliability and Maximum Coordination in the Fight against the Volcano
Best Use of Critical Communications in Transport
Hytera: Kazakhstan Railway Runs Safely and Efficiently with TETRA Communications System
Emerging Technology, Product or Solutions
Hytera PNC560, World’s First 5G MCPTT Device
Recently Hytera has released a number of innovations from its wide range of product lines, including the latest H-Series DMR Radios, Body-worn Cameras, PTToC Radios & MCS Radios, Multi-mode Rugged Radio and 5G Xsecure Rugged Device. Also the newly launched Hytera Convergence-Native Solutions (including HyTalk, HyTalk Pro and HyTalk MC), composed of different modules, integrates existing network infrastructures, unifies the network core and the communication platform, and provides open API for new service deployment.
With cutting-edge critical communication technologies, Hytera will continue to bring value to global customers leveraging its technologies and professionals.
For more information about Hytera at ICCAs 2022, please visit: https://www.hytera.com/en/media-center/event/hytera-group-won-international-critical-communication-awards.html
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005515/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom